Roche sees need for "real" biosimilars, assesses strategy for the sector
This article was originally published in Scrip
Executive Summary
Roche continues to emphasise that biosimilars will never be quite the same as the innovator product, although the company appears to be evaluating its strategic options on how to position itself in the face of potential competition from biosimilars.